What is monitored in Phase 3 clinical trials aside from the drug's effectiveness?

In Phase 3 clinical trials, the primary focus is on assessing the drug's effectiveness; however, it is equally important to monitor side effects and how the drug compares to existing treatments. This phase typically involves a larger patient population and aims to gain insights into the drug's overall safety profile, including adverse reactions that may not have been evident in earlier phases.

Additionally, researchers often compare the new drug's effectiveness against the standard treatments that are currently available. This comparative aspect helps determine whether the new medication offers a significant therapeutic advantage over existing options and provides crucial information for regulatory bodies deciding on approval.

The emphasis on side effects ensures that any potential risks associated with the drug are well understood before it can be made available to the public, informing healthcare providers and patients about the therapy's safety and efficacy. Thus, monitoring side effects and comparative treatments is a critical component of Phase 3 trials, which aids in the comprehensive evaluation of the drug's therapeutic value in real-world settings.